Registers mild growth

The company has employed new strategies to maintain its growth in wake of prevalent not-so-exciting market conditions


Rank: 2
Segment: BioSupplier-Distributor
Organization: Imperial Life Sciences
Director - Sales & Marketing: Mr Neeraj Gupta
Revenue: Rs 219 crore


 Imperial Life Sciences (ILS) has succeeded in retaining its business growth despite the adverse conditions in the market segments of its operation. As against Rs 212 crore registered during the FY2013-14, Imperial recorded Rs 219 crore in the current fiscal year.

The distributor company, known as complete solution provider in the instrumentation, reagents, and molecular diagnostics, has been utilizing every strategy to make its mark felt. It is known for its in-house services on Affymetrix and Agena Platforms along with bioinformatics. Besides this, it has the entire range of products for genomics, proteomics, cell culture, drug discovery and bio-production labs.

The basic plan in Imperial's current marketing strategy is to overcome the challenges of funding crunch in India. Company has managed to balance the sale by collaborating with some of the leading private companies in India especially on providing the services on Pacific Biosciences platforms. ILS executed a project in agri-genomics sector for total 10,000 samples which was a milestone to achieve.
Among the major announcements during 2014-15, the company has also started its in-house projects as a service provider especially on Microarrays and Mass Array technologies at cost-effective pricing. The company also stepped into molecular diagnostic market and is growing the business in this segment at a good pace.

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email